FDA — authorised 28 August 2018
- Application: NDA205054
- Marketing authorisation holder: INVAGEN PHARMS
- Status: supplemented
FDA authorised Lutrate on 28 August 2018
Yes. FDA authorised it on 28 August 2018; FDA has authorised it.
INVAGEN PHARMS holds the US marketing authorisation.